HIV-1 B与BF重组亚型对拉替拉韦耐药突变谱的影响
该研究对30例拉替拉韦治疗病毒学失败的HIV-1感染者进行耐药基因型分析,发现B亚型与F亚型在整合酶耐药突变谱上存在差异,B亚型中Q148K/R/H、G140S和E138K/A更常见,而F亚型突变预测对拉替拉韦耐药水平较低且对第二代整合酶抑制剂无交叉耐药。
要点
- B亚型在拉替拉韦失败时更常见Q148K/R/H、G140S和E138K/A突变。
- F亚型整合酶耐药突变预测对拉替拉韦耐药水平较低,对第二代INI无交叉耐药。
- HIV-1亚型多样性可能影响整合酶抑制剂耐药检测算法和临床用药选择。
核心结论
- B亚型和F亚型整合酶基因组在拉替拉韦治疗失败时沿不同耐药通路进化,对临床实践有影响。
研究设计与样本
- 对30例接受拉替拉韦治疗且病毒学失败的HIV-1感染者进行HIV-1耐药基因型分析,用Stanford HIVdb和系统发育分析表征耐药突变与亚型。
主要发现
- 30条整合酶序列中,14条为F亚型(47%),8条为B亚型(27%),7条为BF重组(23%),1条为疑似CRF05_DF(3%)。
- 25例(83%)同一感染者的蛋白酶和逆转录酶序列证实存在不同BF重组。
- Stanford HIVdb基因型分析与系统发育推断在70%的整合酶序列和60%的PR-RT序列中一致。
- B亚型中Q148K/R/H更常见(63% vs 0%,P=0.0021),G140S更常见(50% vs 0%,P=0.0096),E138K/A更常见(50% vs 0%,P=0.0096)。
- 上述差异独立于拉替拉韦治疗时间或基因型检测时病毒载量。
关键数值与推荐
- F亚型整合酶基因组中的INI耐药突变预测对拉替拉韦耐药水平较低,且对第二代INI无交叉耐药。
临床怎么用
- 临床应考虑HIV-1亚型对整合酶抑制剂耐药突变谱的影响,以优化耐药检测算法和INI使用。
局限性
- 样本量较小(30例),需更大规模研究验证亚型对耐药通路的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current knowledge on HIV-1 resistance to integrase inhibitors (INIs) is based mostly on subtype B strains. This contrasts with the increasing use of INIs in low- and middle-income countries, where non-B subtypes predominate. MATERIALS AND METHODS: HIV-1 drug resistance genotyping was performed in 30 HIV-1-infected individuals undergoing virological failure to raltegravir. Drug resistance mutations (DRMs) and HIV-1 subtype were characterized using Stanford HIVdb and phylogenetic analyses. RESULTS: Of the 30 integrase (IN) sequences, 14 were characterized as subtype F (47%), 8 as subtype B (27%), 7 as BF recombinants (23%) and 1 as a putative CRF05_DF (3%). In 25 cases (83%), protease and reverse transcriptase (PR-RT) sequences from the same individuals confirmed the presence of different BF recombinants. Stanford HIVdb genotyping was concordant with phylogenetic inference in 70% of IN and 60% of PR-RT sequences. INI DRMs differed between B and F IN subtypes, with Q148K/R/H, G140S and E138K/A being more prevalent in subtype B (63% versus 0%, P = 0.0021; 50% versus 0%, P = 0.0096; and 50% versus 0%, P = 0.0096, respectively). These differences were independent of the time on raltegravir therapy or viral load at the time of genotyping. INI DRMs in subtype F IN genomes predicted a lower level of resistance to raltegravir and no cross-resistance to second-generation INIs. CONCLUSIONS: Alternative resistance pathways to raltegravir develop in subtypes B and F IN genomes, with implications for clinical practice. Evaluating the role of HIV-1 subtype in development and persistence of mutations that confer resistance to INIs will be important to improve algorithms for resistance testing and optimize the use of INIs.
引用
- Sánchez D, Arazi Caillaud S, Zapiola I, et al. Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains. J Antimicrob Chemother. 2020. PMID: 32125378. doi:10.1093/jac/dkaa042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。